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Abstract: Urinary bladder cancer is one of the most common cancers worldwide, with the 
highest incidence in industrialized countries. Patients with cancer commonly use 
unconventional and complementary therapy including nutraceuticals. In this study we 
evaluated the efficacy of chitooligosaccharides (in orange juice) in rat bladder cancer 
chemoprevention and as therapeutic agent, on a rat model of urinary bladder 
carcinogenesis induced with N-butyl-N-(4-hydroxybutyl) nitrosamine. Results indicate that 
chitooligosaccharides may have a preventive effect on bladder cancer development and a 
curative effect upon established bladder tumors, dependent on the concentration ingested 
500 mg/kg b.w., every three days, showed capacity to inhibit and prevent the proliferation 
of bladder cancer; however, this was associated with secondary effects such as 
hypercholesterolemia and hypertriglyceridemia. The use of lower doses (50 and 250 mg/kg 
b.w.) showed only therapeutic effects. It is further suggested that this antitumor effect might 
OPEN ACCESS
Mar. Drugs 2012, 10 2662 
 
be due to its expected anti-inflammatory action, as well as by mechanisms not directly 
dependent of COX-2 inhibition, such as cellular proliferation control and improvement in 
antioxidant profile.  
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1. Introduction 
Chitosan, a linear biopolymer comprising glucosamine and N-acetylglucosamine residues (Figure 1), 
is an N-deacetylated product of chitin, one of the most abundant polysaccharide in nature [1]. Due to 
its claimed properties such as antibacterial, antifungal, cholesterol lowering, antioxidant or antitumor 
properties, chitosan has been used as marine-derived nutraceutical in the food and food supplement 
industries [2,3]. However, its high molecular weight (MW)—which hampers solubility in acid-free 
aqueous media, has limited its practical applications [4]. Recent studies have focused on conversion of 
chitosan to oligosaccharides (termed chitooligosaccharides, COS)—because the latter are not only 
readily soluble in water due to their shorter chain lengths (generally, the MW of COS is 10 kDa or 
less) and free amino groups in D-glucosamine units, but also easily absorbed through the intestine, 
quickly getting into the blood flow [5–7]. The aforementioned properties, in addition to the positive 
charge of COS (which allows them to bind strongly to negatively charged surfaces), are responsible for 
many observed biological activities, such as lowering high blood pressure, controlling arthritis, 
treatment of diabetes mellitus and immuno-stimulation, in addition to prebiotic activity [6]. In 
addition, these oligosaccharides have also been reported as responsible for the inhibition of colorectal 
tumors, for example induced by dimethylhydrazine or azoxymethane, in the initiation and promotion 
stage [8–10]. Moreover, the development of sarcoma 180 tumor cells in mice was inhibited by oral 
treatment with COS [11]. Recently, chitosan oligosaccharides were shown to effectively inhibit uterine 
cervix carcinoma in BALB/c mice [6]. 
Figure 1. Structure of chitin and chitosan. Chitin is composed mainly by (b) units while 













Mar. Drugs 2012, 10 2663 
 
Urinary bladder (or bladder) cancer is one of the most common cancers worldwide, with the highest 
incidence in industrialized countries [12]. It is a huge concern for the medical community because of 
its malignancy, as well as high mortality and prevalence rates [12,13]. Furthermore, recurrence rates 
are also high, explaining that prevalence exceeds the primary incidence [14,15]. It is the fourth most 
common tumor in men and the eighth in women, accounting for 5%–10% of all malignancies in 
Western countries [12]. Excepting for superficial forms, bladder cancer prognosis is poor, particularly 
when lately diagnosed or inadequately treated, and is associated with high socioeconomic  
costs [13,16,17]. Despite the advances in medical care, the conventional methods of surgery, 
chemotherapy and radiotherapy have not impacted greatly on the general morbidity and mortality [18,19]. 
Thus, preventive strategies are crucial for the management and treatment of bladder cancer, which will 
depend on a better elucidation of the mechanisms underlying cancer lesion development. The 
carcinogen-induced model of bladder cancer with N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in 
rats is a valuable experimental tool to study human cancer development, namely due to similar 
histological features with the human transitional cell carcinoma [20]. Urothelial transitional cell 
carcinoma is the predominant pathological lesion. The malignant transformation is a continuous 
process that includes dysplasic and proliferative epithelial abnormalities, pre-neoplasic changes and 
malignant lesions (papiloma and carcinoma) [12,21,22]. This model should also be important to 
evaluate the efficacy of modern therapeutic strategies, as it is the use of nutraceuticals [23]. An early 
treatment with agents that reverse these molecular and morphological pathways might hypothetically 
prevent the bladder cancer. Pre-clinical studies using green tea polyphenols, soy products, vitamins, 
selenium and nonsteroidal anti-inflammatory drugs demonstrate that bladder cancer is responsive to 
prevention strategies [24,25]. Others have also shown the efficacy of selective cyclooxygenase-2 
inhibition for bladder cancer chemoprevention in rats [26]. 
Regarding the above features, in this research effort we intended to assess the anticarcinogenic 
effects of COS on a rat model of urinary bladder carcinogenesis induced with N-butyl-N-(4-hydroxybutyl) 
nitrosamine (BBN). 
2. Results and Discussion 
COS3 analysis indicated an average molecular weight (MW) of 1.763 ± 0.7 kDa, and a degree of 
deacetylation (DD) of 64.14 ± 1.96%. 
All 50 rats completed the 20 weeks protocol. No relevant changes were obtained between the 
groups during the study concerning body weight and beverage consumption, although at the end of the 
20 weeks, rats fed with 500 mg/kg COS showed a slightly higher average weight (data not shown), but 
not statistically significant. Our results are in agreement with previous data from this model, 
concerning both the percentage of incidence of tumors and the type of lesions in the BBN rats [27], 
confirming the credibility and value of this model to evaluate chemopreventive efficacy of drugs. All 
formaldehyde pre-fixated bladders were opened and analyzed macroscopically for wall (urothelium) 
texture, thickness and vascularisation (Figure 2).  
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Figure 2. Macroscopic evaluation of the bladders, at the end of the 20 week-protocol:  
A—group control; B—group N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN); C—group 
T-BBN + chitosan oligosaccharides (COS)(50); D—group P-COS(50) + BBN; E—group 
T-BBN + COS(250); F—group P-COS(250) + BBN; G—group T-BBN + COS(500);  
H—group P-COS(500) + BBN. 
 
The percentage of rats with tumor in each group, the number of tumors per rat with tumor, as well 
as the mean tumor volume per rat and per tumor were then evaluated macroscopically (Table 1). All 
the bladders from the group control have revealed a pattern of normality, with absence of any type of 
malignity. The wall texture, thickness and vascularisation were normal (Figure 2A). Similar profile 
was found for the COS control groups (groups COS(250) and COS(500)), with limpid, translucent and 
tiny bladders, without presence of any abnormal mass or vascularisation (data not shown). In the group 
BBN, however, 80% of the rats had bladder tumors, all easily observed due to their large dimensions. 
The bladder walls were thicker, with new or enlarged small vessels, suggesting neo-angiogenesis, and 
there was unequivocal formation of tumor, some of them of relevant volume (Figure 2B). In groups  
P-COS(50) + BBN and P-COS(250) + BBN, all bladders showed a similar pattern to those seen for the 
BBN group—bladder walls were thicker, new small vessels suggested neo-angiogenesis and unequivocal 
formation of tumors, when compared to control group (Figure 2A), signifying that at these concentrations 
(i.e., 50 and 250 mg/kg) COS have insignificant effects preventing bladder cancer (Figure 2C,F).  
In groups T-BBN + COS(50) and T-BBN+COS(250) we observed a dose-dependent therapeutic 
effect—a higher treatment dose resulted in higher treatment effectiveness; the mean number of tumors 
per rat and the mean number of tumors per rat with tumor, were significantly lower on both groups, 
compared to group BBN; the volume per tumor was also considerably lower (Figure 2D,E); however, 
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all the described parameters were significantly lower in group T-BBN + COS(250), compared to group 
T-BBN + COS(50). 
Table 1. Results of the macroscopic (quantitative) and microscopic (qualitative) evaluation 
of urothelium lesions. 
Rat Groups (n = 5 each) 1 2 3 4 5 6 7 8 9 10 
Macroscopic analysis 
Number of tumors 
% of tumors/group 0 40 100 0 20 80 0 20 25 80 
Total no. of tumors 0 2 9 0 1 5 0 1 2 9 
No. of tumors/rat 0 0.4 1.8 0 0.2 1 0 0.2 0.4 1.8 
Tumor volume 
Per tumor (mm3) 0 2.6 3.22 0 1.04 3.25 0 1.04 1.3 4,49
Microscopic (histological) analysis 
Pre-neoplastic lesions 
Hyperplasia 0 1/2 6/9 0 0 2/5 0 0 0 5/9 
High-grade dysplasia 0 1/2 3/9 0 1/1 2/5 0 1/1 0 4/9 
Malignant lesions, tumor 
Papillary 0 1/2 9/9 0 1/1 4/4 0 1/1 1/2 7/9 
Infiltrative 0 0 0 0 0 0 0 0 0 2/9 
Tumor grading 
Low grade (G1) 0 1/2 5/9 0 0 3/4 0 0 1/2 3/9 
High grade (G2/G3) 0 1/2 4/9 0 1/1 1/4 0 1/1 1/2 6/9 
Values are mean (SEM) or n variable. 1: control; 2: T-BBN + COS(50); 3: P-COS(50) + BBN; 4: COS(250); 
5: T-BBN + COS(250); 6: P-COS(250) + BBN; 7: COS(500); 8: T-BBN + COS(500); 9: P-COS(500) + BBN; 
and 10: BBN. 
In both groups T-BBN + COS(500) and P-COS(500) + BBN, a marked inhibition on bladder tumor 
growth was observed (Figure 2G,H). Although the preventive group (group P-COS(500) + BBN) 
showed higher efficiency, both groups reduced significantly the number of tumors and respective 
volume, when compared to BBN group; in fact, this was the only concentration where a preventive 
effect was seen. 
Histological examination (Figure 3) showed less aggressive histological changes in all groups 
treated with COS than in the control group with BBN (group BBN). The bladder from negative control 
animals (group control) had no signs of pre-neoplasic lesions (neither hyperplasia nor dysplasia), as 
well as those from the COS control groups (groups COS(250) and COS(500)). In the carcinogen 
(BBN) group, there was evident malignant transformation, including hyperplasia and dysplasia, 
present in all the animals, including the one without tumor formation. Furthermore, there were also 
malignant lesions—papillary and infiltrative (Table 1). 
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Figure 3. Microscopic histomorphology (H & E). The typical bladder from control group 
(A) and control groups with COS (B) treated-rats had no signs of pre-neoplasic lesions or 
gross tumor formation. In the carcinogen groups, the bladder from several animals 
presented hyperplasia (C and D) (groups T-BBN + COS(50), P-COS(250) + BBN and 
BBN) and high-grade dysplasia (E and F) (groups T-BBN + COS(50), P-COS(50) + BBN, 
T-BBN + COS(250), P-COS(250) + BBN, T-BBN + COS(500) and BBN), including those 
without tumor formation, as well as malignant lesions, such as papillary tumors (G and H) 
(groups 2, 3, 5, 6, 8, 9 and 10) or infiltrative (I) (group 10). 
 
The use of COS as therapeutic has notoriously decreased bladder cancer progression, at all tested 
concentrations (i.e., groups T-BBN + COS(50), T-BBN + COS(250) and T-BBN + COS(500)). In these 
groups, whose urothelia only demonstrated hyperplasia (only one animal in group T-BBN + COS(50)) 
and dysplasia (one animal in each of the three groups), the few tumors seen were all papillary.  
When used in a preventive way, no pre-neoplastic lesions were observed at 500 mg/kg (group  
P-COS(500) + BBN), with only one papillary tumor. However, at lower doses (group P-COS(50) + BBN 
and P-COS(250) + BBN) the number of malignant lesions was much higher, nevertheless all tumors 
were papillary. Histological examination of these two groups showed, opposite to macroscopic 
examination, some preventive effect, but almost negligible compared to group P-COS(500) + BBN. 
The antiproliferative activity of COS was reported in several preclinical studies, including cell-line 
cultures of human leukemia and breast cells and in vivo studies upon mouse sarcoma-180, fibrosarcoma, 
uterine cervix tumor or Ehrlich ascites tumors in rats and mice [6,28–31]. The mechanisms underlying 
the anticarcinogenic properties of COS remain to be fully elucidated, but the most accepted 
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mechanism states that COS may inhibit the growth of tumor cells by immunoenhancement rather than 
directly damaging the tumor cells. It is suggested that the antitumor activity of water soluble  
chitosans and COS might be related, in part, to an enhancement of the proliferation of cytolytic 
lymphocytes—natural killer cells [6,11]. However, lymphocytes count in this study did not reveal any 
significant difference, and therefore does not sustain this hypothesis (data not shown).  
It is largely accepted that the mechanisms underlying cancer appearance and progression are 
multifactorial. Inflammation, through its mediators (cytokines and other growth factors), seems to be 
one of the main contributors for cancer growth. One of the mechanisms more closely linked to 
inflammation is the pathway of COX enzymes, in particular COX-2 [32], whose levels and activity 
have been reported to be elevated in several types of cancers [33]. A chemopreventive role for COX-2 
inhibition in bladder cancer was previously reported in animal models [34–36], but the mechanisms by 
which these compounds are able to act on carcinogenesis remain to be elucidated. Furthermore, a key 
role for COX-2 in carcinogenesis has been given by the positive effect of its down-regulation on 
tumors incidence both in clinical and experimental studies for distinct types of tumors, including the 
bladder cancer [37–40]. In a previous study we concluded that COS possess anti-inflammatory activity 
involving the inhibition of the cyclooxygenase pathway [41]. In addition, Lee et al., also reported that 
COS may exert an anti-inflammatory effect via down-regulation of transcriptional and translational 
expression levels of COX-2 [42]. Therefore, it is suggested here that the anticarcinogenic activity 
shown by COS may be related to its capacity to down-regulate expression levels of COX-2. This 
hypothesis merits further elucidation, which could be done assessing COX-2 expression and activity. 
The lipid profile showed that a 500 mg/kg COS dose caused hypercholesterolaemia and 
hypertriglyceridaemia in all the three groups treated with this dose (COS(500), T-BBN + COS(500) 
and P-COS(500) + BBN) (Table 2). In addition, liver weight was considerably heavier than in the 
control group (P < 0.01) (data not shown). Rats in group P-COS(250) + BBN presented changes in 
hepatic function, with significantly elevated values of AST and ALT. No other significant biochemical 
or organ weight changes were perceived. Concerning hematology parameters (data not shown), groups 
COS(500), T-BBN + COS(500) and P-COS(500) + BBN presented higher values for hematocrit, red 
blood cells count and hemoglobin, however, were statistically not significant. In the opposite position, 
group P-COS(250) + BBN showed lower values for the same parameters than the other groups, though 
only the difference on reticulocyte values was significant.  
The liver and kidney malondialdehyde (MDA) content, a lipidic peroxidation marker, was 
unchanged between the control and the BBN groups (Figure 4). In addition, groups treated with 50 and 
250 mg/kg of COS also showed similar MDA profile, however, in the groups given a 500 mg/kg dose 
(i.e., groups COS(500), T-BBN + COS(500) and P-COS(500) + BBN), there was a significant 
decrease in both liver (p < 0.001) and kidney (p < 0.001) MDA content. Serum MDA concentration 
showed an opposite trend, since in this case the 500 mg/kg groups (groups T-BBN + COS(500) and  
P-COS(500) + BBN) showed significantly higher values (p < 0.05) than both control groups. Total 
antioxidant status (TAS) did not present significant differences between the 10 groups. However, the 
positive control group (i.e., group BBN) and groups T-BBN + COS(50), P-COS(50) + BBN and  
P-COS(250) + BBN showed lower TAS values when compared with all the other groups. 
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Table 2. Biochemical data for the 10 groups at the end of the study (week 20). 
 Group 







































































































































































































































* Non-Gaussian distribution (median–inter-quartile range); # Normal distribution (mean–standard deviation). 1: negative control group; 2: 50 mg/kg COS therapeutic 
group; 3: 50 mg/kg COS preventive group; 4: 250 mg/kg COS control group; 5: 250 mg/kg COS therapeutic group.; 6: 250 mg/kg COS preventive group; 7: 500 mg/kg 
COS control group; 8: 500 mg/kg COS therapeutic group; 9: 500 mg/kg COS preventive group; and 10: BBN control group. G.P.T.—Glutamic-Pyruvic Transaminase; 
G.O.T.—Glutamic-Oxaloacetic Transaminase. 
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Figure 4. Redox status markers: lipidic peroxidation (MDA content) in liver (A), kidney (B) 
and serum (C); serum TAS (D).  
 
In this study, apart from the above reported anti-proliferative effect, the positive impact of COS3 on 
bladder cancer chemoprevention/treatment seems also to be related with a beneficial influence on redox 
status. Even though the lower values of MDA in serum, the positive effect of a 500 mg/kg treatment 
seem to be extended to the redox status, given by the remarkable shift to the antioxidant capacity in the 
liver and kidney, as well as a high capacity avoid reactive oxygen species (ROS) formation. 
Inflammation, proliferation and oxidative stress seem to be important for bladder carcinogenesis [30]. 
We have demonstrated in this study that the use of COS3, in the stage of cancer initiation, or even 
before, as chemopreventive therapy, has a notable effect dose dependent, on cancer appearance and 
progression, which might be particularly useful for individuals of higher risk as well as for patients 
treated for an previous episode of bladder cancer and under high risk of recurrence [14,15]. 
3. Experimental Section  
3.1. COS Characterization (MW and DD) 
COS derived from crab shells, named COS3, were purchased from Nicechem (Shanghai, China). 
The average MW of COS3 was assessed by size exclusion chromatography (SEC). Two combined 
TSKGel series columns (G2500PWXL × G5000PWXL) together with a PWXL guard column were used, 
coupled with a RID-10A Shimadzu refractive index (RI) detector. A flow rate of 0.8 mL·min−1 and a 
mobile phase solution of 0.5 M AcOH–0.2 M AcONa at pH 4.4–4.5 (25 °C), were found to be the 
most suitable conditions to evaluate COS molecular weight. Pullulan (TOSOH Biosciences) of 
different molecular weights were used as standards to calibrate the column, and quantification of COS 
was performed by external calibration, using chitobiose as standard. Data provided by the SEC-HPLC 
system were collected and analyzed using the Chromeleon system version 6.7. The DD was 
determined using a FT-IR Perkin Elmer infrared spectrometer. An aliquot of COS sample was mixed 
with potassium bromide (1:1000) and compressed into pellets. The IR spectra were recorded and the 
absorbance values of the suitable absorption bands were calculated using the base line method. The 
DD was calculated from the value of the absorption band ratio Aamide peak/Areference peak. A number of 
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absorption band ratios have been proposed in the literature, differing either in the band selected as in 
the internal reference band. One such band ratio is A1655/A3450, determined using a line draw from  
4000 cm−1 to 2500 cm−1 as the base line for the hydroxyl group band, and one drawn from 1800 cm−1 
to 1600 cm−1 as the base line for the amide I band. The DD was thus calculated according to the 
following equation [43],  
[DD (%) = 100 − (A1655/A3450) × 115] (1)  
3.2. Animals and Treatment  
Fifty male Wistar rats (Charles River Laboratory Inc, Barcelona, Spain), 250–285 g, 8 weeks old, 
were maintained in an air-conditioned room, subjected to 12-h dark/light cycles and given standard 
laboratory rat chow (IPM-R20, Letica, Barcelona, Spain) and free access to tap water. Animal 
experiments were conducted according to the European Communities Council Directives on Animal 
Care. The rats were divided into 10 groups (n = 5 each): 1, Control group—orange juice only;  
2, T-BBN + COS(50)—treatment group receiving daily 0.05% BBN and 50 mg/kg of COS in every  
3 days; 3, P-COS(50) + BBN—preventive group receiving 50 mg/kg in every 3 days of COS and 
0.05% BBN; 4, COS(250) Control—receiving only 250 mg/kg of COS in every 3 days;  
5, T-BBN + COS(250)—treatment group receiving daily 0.05% BBN and 250 mg/kg of COS in every  
3 days; 6, P-COS(250) + BBN—preventive group receiving 250 mg/kg in every 3 days of COS and 
0.05% BBN; 7, COS(500) Control—receiving only 500 mg/kg of COS in every 3 days;  
8, T-BBN + COS(500)—treatment group receiving daily 0.05% BBN and 500 mg/kg of COS in every 
3 days; 9, P-COS(500) + BBN—preventive group receiving 500 mg/kg in every 3 days of COS and 
0.05% BBN; and 10, BBN group—carcinogen group receiving 0.05% BBN (Tokyo Chemical Industry 
Co., Ltd., Tokyo, Japan). The experimental study was conducted in two steps, a tumor-induction phase 
from week 1 to week 8, when rats from groups 2, 3, 5, 6, 8, 9 and 10 received BBN ad libitum in 
orange juice (preventive groups—3, 6 and 9, received COS at the same time), and a treatment phase 
from week 8 to week 20, when rats in groups 2, 5 and 8 received COS at different concentrations by an 
oesophageal cannula. All rats completed the 20-week study protocol, and body weight and amount of 
drunken liquid were monitored during the experimental period. All procedures involving animals were 
in accordance with the Association for Pharmacology and Experimental Therapeutics, and approved 
by the Institutional Ethics Committee of the Faculty of Medicine from the University of Coimbra. 
Approval ID: FMUC/09/10. 
3.3. Blood and Organs Collection  
At the end of treatment the rats were anaesthetised intraperitoneal with 2.0 mg/kg of a 2:1 (v:v)  
50.0 mg/mL ketamine (Ketalar®, Parke-Davis, Pfizer Laboratories Lda, Seixal, Portugal) solution in 
2.5% chlorpromazine (Largatil®, Rhône-Poulenc Rorer, Vitória Laboratories, Amadora, Portugal). 
Blood samples were immediately collected by venepuncture from the jugular vein in needles with no 
anticoagulant (for serum samples collection) or with EDTA. Under anaesthesia the rats were killed by 
cervical dislocation, and the liver, kidneys and heart immediately removed, weighed and placed in  
ice-cold Krebs buffer or formaldehyde for further analysis. Before removal, bladders were 
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intraluminally injected with a buffered formaldehyde solution as pre-fixation for histological analyses. 
A ligature was placed around the bladder neck to maintain proper distension.  
3.4. Blood Analysis 
Several haematological variables were measured in EDTA-whole blood using an automatic Coulter 
Counter® (Beckman Coulter Inc., Foster City, CA, USA), i.e., a red blood cell count, hematocrit, 
haemoglobin concentration, platelet and white blood cells count. 
3.5. Macroscopic Tumor Analysis 
For a macroscopic quantitative analysis (number and volume of tumors), each bladder pre-fixed in 
formaldehyde was carefully opened, the lumen inspected for grossly visible lesions and the number of 
tumors per rat and the volume of each tumor were recorded to calculate the incidence of tumor per 
group and the mean volume per rat. A tumor was defined as a lesion of >0.5 mm in diameter.  
3.6. Microscopic Tumor Analysis 
For the microscopic qualitative analysis (bladder histology), the bladder was immersion-fixed in  
4% buffered formaldehyde and processed for paraffin sectioning [44]. Three slices from each bladder 
were embedded, 3 μm sections cut and stained with hematoxylin and eosin (H & E), and examined 
histologically by one author (Cunha MFX) unaware of the treatments.  
3.7. Antioxidant Capacity 
Serum redox status was assessed by two methods: a thiobarbituric acid reactive species assay, in 
which serum was used to determine the products of lipid peroxidation, i.e., malondialdehyde (MDA), 
as previously described [45]; and a ferric reducing antioxidant potential (FRAP) assay, in which serum 
antioxidant capacity was measured as FRAP, as previously described [46], and termed the total 
antioxidant status (TAS). 
3.8. Statistical Analysis 
Mean values and standard deviations were accordingly calculated from the obtained experimental 
data. Because several of the studied variables presented a non-Gaussian distribution, we present that 
data as median (interquartile range) values. For statistical analysis, we used the Statistical Package for 
Social Sciences (SPSS) version 15.0 for Windows. To evaluate the differences between groups, we 
used the nonparametric Kruskal-Wallis H test. When statistical significance was achieved, single 
comparisons (two groups) were made by the use of the Mann-Whitney U test. A p value of <0.05 was 
considered to be statistically significant. 
4. Conclusions  
In conclusion, our study demonstrates that application of COS3 has a preventive effect on bladder 
cancer appearance, as well as it can be successfully used as a curative beneficial ingredient, dependent 
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on the concentration. This antitumor effect might be due to its expected anti-inflammatory action, in 
addition to other mechanisms not directly dependent of COX-2 inhibition, such as cellular proliferation 
control and improvement in antioxidant profile.  
Although this was a preliminary study, the results are promising and justify further investigation, 
including other dosages, to validate the role of cancer chemoprevention strategies based on the 
therapeutic use of COS, as well as to further investigate possible secondary effects, mainly in liver. 
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